No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 32 of the 40 quarters in the window, leaving 8 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:37.411Z. Latest historical point 2024-06-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:20:37.411Z. Latest historical point 2026-01-12.
The latest delayed quote for Anixa Biosciences, Inc. (ANIX) stock was $2.95 as of Oct 5, 2026, 4:00 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months -9.7% · 3-year avg -6.8%/yr · 5-year avg -8.3%/yr
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines.
Biotechnology · San Jose, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2019-10-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2012-10-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Jan 11, 2027
97 days away
EPS Estimate
-0.08
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.08
vs Estimate
$-0.08
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ANIX | $100.37M | $2.95 | +0.00% | -9.74% | -8.26% | -4.65% | N/A |
| 2KRRO | $99.24M | $9.97 | +3.42% | -78.27% | -50.72% | N/A | vs ANIX |
| 3JYNT | $102.43M | $7.18 | -1.30% | -20.73% | -40.34% | +11.23% | vs ANIX |
| 4DH | $104.07M | $0.99 | +5.67% | -70.99% | -52.54% | N/A | vs ANIX |
| 5CPIX | $106.23M | $7.09 | -4.06% | +172.53% | +25.62% | +5.52% | vs ANIX |
| 6BMEA | $93.99M | $1.30 | +2.36% | -39.39% | -36.56% | N/A | vs ANIX |
forward FY estimate
N/A
Consensus Rating
Based on 4 analysts
Average Price Target
$9.75
+230.5% upside
Low
$6.00
Current
$2.95
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Jan 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Apr 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Jul 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| FY 2027 | $-0.32 | $-0.32 | $-0.32 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jan 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Apr 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jul 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $34.00M | $34.00M | $34.00M | 4 |
